Last updated Jun 7, 2026
Roche
Evidence Sources
8
Competitive Findings
0
Portfolio Developments
10
Regulatory Precedents
8
Clinical Programs
4
Confidence Coverage
74%
Audit
- Competitor findings: 0
- Portfolio developments: 10
- Self-competition findings removed: 10
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Obesity
- Triple Agonist
- Oncology
- Supportive Care
- Ophthalmology
Highest priority development: Regulatory Developments Reshape Competitive Landscape in Oncology Supportive Care
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 74%
Active Signals
6
Investigate Priority
0
Opportunity Score
245
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 7, 2026Score 48FDA Grants AP Status for MESNA ANDA203364 Submission by RISING
Oncology · Supportive Care
- MonitorJun 7, 2026Score 44Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial
Obesity · Triple Agonist
- MonitorJun 7, 2026Score 41FDA Accepts Supplement for VABYSMO by Genentech
Ophthalmology · Anti-VEGF
Related Assets
Portfolio asset pages with evidence-based assessments.
- Regulatory Developments Reshape Competitive Landscape in Oncology Supportive CareModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera - Lilly's Retatrutide Trial Results Disrupt Obesity Treatment LandscapeModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera - Regulatory Developments in OphthalmologyModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)RocheFDAPortfolio
- Low Confidence · 0%Sources (3)RocheFDAPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Prime Food Processing LLC Issues Safety Warning Regarding Uneviscerated “Dried Herring Fish”High Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Newly Added Guidance DocumentsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Recently Issued Guidance DocumentsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Drugs@FDA Data FilesModerate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Regulatory Developments Reshape Competitive Landscape in Oncology Supportive CareModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov - Lilly's Retatrutide Trial Results Disrupt Obesity Treatment LandscapeModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov - Regulatory Developments in OphthalmologyModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Roche right now?
- Which regulatory precedents should Roche monitor in Obesity and Triple Agonist?
- How does Regulatory Developments Reshape Competitive Landscape in Oncology Supportive Care compare to the nearest competitive programs?
- What signals require immediate investigation for Roche?
- Summarize the strategic implications of recent developments for Roche.
- Where is the greatest uncertainty in Roche's competitive positioning?